The ankylosing spondylitis drugs market globally reached USD 7.25 billion in 2022 and is anticipated to reach USD 13.33 billion by 2032, with a projected revenue compound annual growth rate (CAGR) of 7% during the forecast period. The increasing prevalence of ankylosing spondylitis, coupled with a growing demand for safe and effective treatment options and improved awareness about the...
English
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Português
Ελληνικά
Tiếng Việt